Literature DB >> 11285378

Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis.

B Möller1, N Kukoc-Zivojnov, U Kessler, S Rehart, J P Kaltwasser, D Hoelzer, U Kalina, O G Ottmann.   

Abstract

OBJECTIVES: To investigate the expression of and monokine induction by interleukin 18 (IL-18; also called interferon-gamma inducing factor, IGIF), in peripheral blood mononuclear cells (PBMC) and cultured synoviocytes from rheumatoid arthritis (RA) patients.
METHODS: We carried out IL-18 Western blotting and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) of cytokines in PBMC [IL-18, IL-1beta and tumour necrosis factor alpha (TNF-alpha)] and long-term cultured fibroblast-like synoviocytes (FLS) [IL-18, IL-1beta, TNF-alpha, IL-6, interferon gamma (INF-gamma) and [granulocyte-macrophage colony stimulating factor (GM-CSF)] from RA patients and controls. FLS were isolated from RA synovial membranes (FLS(SM)) and RA synovial fluids (FLS(SF)), osteoarthritis (OA) FLS(SM) and FLS(SF) from spondyloarthropathy patients. FLS were characterized by fluorescence-activated cell sorting of the FLS. PBMC and FLS from RA patients and control subjects were stimulated with recombinant human IL-18 and IL-1beta (rHuIL-18/rHuIL-1beta), and TNF-alpha, IL-1beta and MMP-1 were measured by ELISA in supernatants.
RESULTS: Constitutive expression of IL-18 mRNA was significantly reduced whereas that of TNF-alpha was enhanced in RA PBMC. Persistent low expression of IL-18, TNF-alpha, GM-CSF and IL-1beta was observed in RA and OA FLS(SM) as well as spondyloarthropathy FLS(SF). In contrast, high constitutive expression of IL-18 in FLS (CD90/Thy-1- and CD54-positive, CD14- and CD86-negative), accompanied by persistent high levels of TNF-alpha, GM-CSF and IL-1beta expression, was restricted to synovial fluid-derived FLS obtained from RA patients. IFN-gamma was not detectable in any culture, but IL-6 mRNA was equally expressed in all FLS cultures. rHuIL-18 was effective in stimulating TNF-alpha and IL-1beta secretion in PBMC from healthy controls, but failed to stimulate TNF-alpha and IL-1beta secretion from PBMC in 11 of 12 RA patients, and all FLS cultures. rHu-IL-1beta, but not rHu-IL-18, induced interstitial collagenase (MMP-1) in FLS.
CONCLUSIONS: Persistent high production of proinflammatory cytokines in RA-FLS(SF) may be relevant for chronic progression in RA synovitis. Levels of TNF-alpha and IL-1beta expression are increased in RA-FLS(SF), but are independent of IL-18. The pathological function of enhanced IL-18 expression in RA-FLS(SF) remains to be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285378     DOI: 10.1093/rheumatology/40.3.302

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

1.  Construction of a recombinant adenovirus vector expressing IL-18BP/IL-4 fusion gene and the anti-inflammatory effect induced by this gene on lipopolysaccharide-stimulated synovial fibroblasts.

Authors:  Hang-Ping Yao; Yun Qian; Xue-Ting Shao; Zhe-Rong Xu; Lin-Fang Cheng; Lei Feng; Nan-Ping Wu; Yun-Mei Yang
Journal:  Inflamm Res       Date:  2009-11-22       Impact factor: 4.575

2.  Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjögren's syndrome, rheumatoid arthritis and healthy controls.

Authors:  P Eriksson; C Andersson; C Ekerfelt; J Ernerudh; T Skogh
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

3.  Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis.

Authors:  Jeffrey H Ruth; Christy C Park; M Asif Amin; Charles Lesch; Hubert Marotte; Shiva Shahrara; Alisa E Koch
Journal:  Arthritis Res Ther       Date:  2010-06-16       Impact factor: 5.156

4.  Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis.

Authors:  T Rooney; E Murphy; M Benito; P Roux-Lombard; O FitzGerald; J-M Dayer; B Bresnihan
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

5.  Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis.

Authors:  Xue-Ting Shao; Lei Feng; Li-Juan Gu; Li-Juan Wu; Ting-Ting Feng; Yun-Mei Yang; Nan-Ping Wu; Hang-Ping Yao
Journal:  Clin Exp Med       Date:  2009-02-19       Impact factor: 3.984

6.  Unique gene expression profile in osteoarthritis synovium compared with cartilage: analysis of publicly accessible microarray datasets.

Authors:  Robin Park; Jong Dae Ji
Journal:  Rheumatol Int       Date:  2016-03-04       Impact factor: 2.631

7.  Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus.

Authors:  C K Wong; C Y Ho; E K Li; L S Tam; C W K Lam
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

8.  Gene expression of Interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy.

Authors:  Sabeen Khalid; Muhammad Javad Yousaf; Amir Rashid; Saleem Ahmad Khan
Journal:  Pak J Med Sci       Date:  2019       Impact factor: 1.088

9.  Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells.

Authors:  Sybille Franke; Manfred Sommer; Christiane Rüster; Tzvetanka Bondeva; Julia Marticke; Gunther Hofmann; Gert Hein; Gunter Wolf
Journal:  Arthritis Res Ther       Date:  2009-09-07       Impact factor: 5.156

10.  Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate.

Authors:  Michele Bombardieri; Francesca Barone; Valerio Pittoni; Cristiano Alessandri; Paola Conigliaro; Mark C Blades; Roberta Priori; Iain B McInnes; Guido Valesini; Costantino Pitzalis
Journal:  Arthritis Res Ther       Date:  2004-08-03       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.